HYFT · MindWalk Holdings Corp.
Market Cap
$60.77M
Shares
47.11M
Volume · Oct 21
96.93K
Avg daily vol (3M)
240.88K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.29
Open$1.34
Day$1.27–1.39
52W close$1.02–2.78
Avg vol 30d309K
Short int707K · 1.5% float · 2.9d
Short vol30%
Last earningsSep 14, 2026
DataJan 2020–Oct 2026
Up next
Next earnings call
Jan 5, 2027
Est · unconfirmed
· in 11 wks
call held Sep 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$11.72M
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+21.3%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-14.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.2%
Year over year · more shares
Price change (1Y)
-21.3%
Trailing year
Short interest
1.5%
Latest settlement · 2.9 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−11%
below
Price vs 50-day avg
−6%
below
RSI (14)
44
neutral
MACD trend
Negative
52-week position
15%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−13%
trailing
6-month return
+8%
trailing
YTD return
−29%
this year
Relative strength
0%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
1 of 27 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.50% of float · ▼ -3.1% MoM · 2.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
27 holders — mid 3-yr range
Squeeze score
47
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
91%
annualized · 1-yr
Max drawdown
−63%
past year
ATR
8.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−11%
Bearish
Price vs 50-day avg
−6%
Bearish
RSI (14)
44
Neutral
MACD trend
Negative
Bearish
52-week position
15%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
1 of 27 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.50% of float · ▼ -3.1% MoM · 2.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
27 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 15%
Range high $3
vs 200-day avg -11%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HYFT
this stock
MindWalk Holdings Corp.
|
$60.77M | -29.1% | — | — | 1.5% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$131.39B | +13.5% | +46.2% | 30.2 | 1.8% |
|
MRNA
Moderna, Inc.
|
$96.65B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.13B | +4.6% | +20.8% | 20.0 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.34B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
SEC Filings
Latest
6-K
- Filed
- Oct 21, 2026
- This year
- 32
MindWalk Holdings Corp. reported that LensAI screened 890,634 antibody sequences in 4 hours and 41 minutes on Amazon EC2 Hpc8a instances powered by AMD EPYC processors, delivering up to 43% lower cost per sequence than an Intel configuration.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HYFT | -12.8% | -12.8% | +8.4% | -2.6% | -29.1% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -11.7% | -12.3% | +0.3% | -3.5% | -41.9% |